Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Meclizine

Classification: B

Drug products: Postafen®

ATC code: R06AE05

Summary

Published controlled studies on differences between men and women regarding safety and pharmacokinetics of meclozine/meclizine are lacking.
 
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.

Additional information

Meclozine in English literature is known as meclizine.

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics of meclizine have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of meclizine have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of meclizine have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Updated: 2019-02-26

Date of litterature search: 2016-12-13

References

  1. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-12-19.] Socialstyrelsens statistikdatabas

Authors: Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson